Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TGR-1202+ brentuximab vedotin · 1 trial · 1 indication
To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities
| Arm | Type | Description |
|---|---|---|
| TGR-1202 + brentuximab vedotin | EXPERIMENTAL | TGR-1202 oral daily dose in combination with a fixed IV infusion of brentuximab vedotin |
| Name | Type | Description |
|---|---|---|
| TGR-1202 + brentuximab vedotin | DRUG | TGR-1202 an oral daily dose with an IV infusion of brentuximab vedotin |
Inclusion Criteria: * Confirmed diagnosis of Hodgkin's Lymphoma * Relapsed or refractory after an autologous stem cell transplant (ASCT) or at least two prior multi-agent chemotherapy regimens in patients not candidates for ASCT * Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 Exclusion...
TGR-1202 is an investigational small molecule being studied for the treatment of hematologic malignancies and solid tumors. In clinical trials, it has been evaluated in patients with Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, and Pancreatic Cancer, among other conditions.
TGR-1202 is a PI3K delta inhibitor. It targets the delta isoform of phosphoinositide 3-kinase, an enzyme involved in cell growth and survival that is often overactive in certain cancers. By inhibiting this target, TGR-1202 aims to disrupt cancer cell proliferation.
TGR-1202 is being developed by TG Therapeutics, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol TGTX on the NASDAQ exchange.
TGR-1202 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. All completed trials for TGR-1202 were Phase 1 studies, and the drug remains in early-stage clinical testing.
TGR-1202 has been studied in several completed Phase 1 trials. These include NCT01767766 in relapsed or refractory hematologic malignancies, NCT02164006 in combination with brentuximab vedotin for Hodgkin's Lymphoma, NCT02268851 with ibrutinib in CLL or MCL, and NCT02574663 in solid tumors.
Yes, TGR-1202 is also known as umbralisib. The drug has been referred to by both names in clinical research and development contexts. This alternative name is used interchangeably with TGR-1202 in scientific literature and trial documentation.